Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2018 Nov 13;18(2):346–355. doi: 10.1158/1535-7163.MCT-18-0510

Figure 5. MTORC1/2 inhibition suppresses growth and MTOR signaling in isogenic human colon cancer cells with and without the PIK3CAH1047R hotspot mutation.

Figure 5.

SW48 human colon cancer cells were treated with increasing concentrations of BEZ235, TAK-228 or control (A). The WST-1 cell proliferation assay was utilized to measure cell viability. Similarly, SW48 cells possessing the PIK3CAH1047R hotspot mutation (SW48PK) were treated with BEZ235, TAK-228, or control with response measured with the WST-1 assay (B). Inhibition of the phosphorylation of RPS6 and 4EBP1 were greater with TAK-228 (10nM) than BEZ235 (10nM) or control after 24 hours of treatment (C).